United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 8,000 shares of United Therapeutics stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $572.38, for a total transaction of $4,579,040.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,188,830.94. This represents a 16.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Down 1.3%

UTHR stock traded down $7.68 during trading on Wednesday, hitting $570.75. 314,854 shares of the stock traded hands, compared to its average volume of 479,013. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The stock has a market cap of $24.23 billion, a price-to-earnings ratio of 21.07, a P/E/G ratio of 1.84 and a beta of 0.60. The company has a 50 day simple moving average of $564.81 and a 200 day simple moving average of $513.93.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 EPS. As a group, analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC grew its position in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the period. Bull Harbor Capital LLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $494,000. Strategic Investment Advisors MI grew its position in shares of United Therapeutics by 20.5% during the 1st quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock worth $5,782,000 after buying an additional 1,662 shares during the period. Talon Private Wealth LLC acquired a new stake in shares of United Therapeutics during the 1st quarter worth approximately $3,038,000. Finally, Royal Bank of Canada grew its position in shares of United Therapeutics by 3.3% during the 1st quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock worth $35,075,000 after buying an additional 1,864 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently commented on UTHR shares. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. UBS Group increased their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Finally, Royal Bank Of Canada decreased their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.